Ozempic and Smoking Cessation: Clinical Evidence and Genetic C...

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

While Ozempic (semaglutide) is FDA-approved for type 2 diabetes and weight management, emerging research suggests GLP-1 receptor agonists may reduce smoking urges in some patients. A 2023 analysis found smoking rates decreased in GLP-1 trial participants, though this was not a primary endpoint. The mechanism likely involves reward pathway modulation and reduced nicotine cravings.

Smoking cessation is multifactorial—involving nicotine dependence, behavioral habit, and individual neurobiological factors. Understanding your genetic predispositions in dopamine signaling and appetite regulation may help contextualize why certain treatments work differently for different people. PlexusDx precision-wellness approach integrates genetic insights to support a more tailored cessation conversation with your provider.

How GLP-1 Agonists May Affect Smoking Behavior

GLP-1 receptors are expressed in brain regions associated with reward, including the nucleus accumbens and ventral tegmental area. These areas regulate dopamine release and are central to nicotine addiction. By modulating these pathways, GLP-1 agonists may reduce the reward signal associated with smoking.

Clinical observations from semaglutide and tirzepatide trials show incidental smoking reduction, though formal smoking cessation studies are limited. Patients reported reduced cravings and decreased pleasure from cigarettes. This suggests GLP-1 agonists may work as adjunctive support alongside behavioral interventions and approved smoking cessation medications.

Evidence From Clinical Trials and Real-World Data

Current evidence comes primarily from observational data within weight-loss and diabetes trials rather than dedicated smoking cessation studies. A 2023 retrospective analysis of GLP-1 users found smoking rates declined by approximately 25–30% in trial arms, though causality was not formally established. Larger, prospective smoking cessation trials are underway.

Study Type	Finding	Sample Size	Limitation
Trial observations	Smoking rates decreased 25-30% in GLP-1 arms	Thousands across multiple trials	Smoking was secondary outcome, not primary endpoint
Real-world data	Anecdotal reports of reduced cravings and pleasure	Case reports and online forums	Lacks formal control group and standardized assessment
Mechanism studies	GLP-1 activation modulates dopamine and reward pathways	Preclinical and neuroimaging data	Limited human data on smoking-specific outcomes
Dedicated cessation RCTs	Preliminary data expected 2024-2025	Ongoing studies	Results not yet published in major journals

Genetic Predispositions in Dopamine and Reward Signaling

Smoking addiction involves complex genetic factors. Variants in dopamine-related genes (DRD2, COMT) and nicotinic acetylcholine receptor genes influence nicotine dependence severity and cessation success. While GLP-1 agonists do not directly target these genes, understanding your genetic predisposition may help identify why you respond differently to cessation strategies.

PlexusDx Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways—markers that relate to appetite and metabolic reward. Although these variants do not directly encode smoking behavior, they may provide context for how your brain processes reward signaling more broadly, potentially informing which combination of interventions your provider recommends.

Safety, Efficacy, and Who Should Consider This Approach

GLP-1 agonists are not FDA-approved for smoking cessation and should not replace established treatments like nicotine replacement therapy, varenicline (Chantix), or behavioral counseling. Common side effects include nausea, vomiting, and gastrointestinal upset—which may actually reduce smoking urges but require monitoring. Contraindications include personal/family history of thyroid cancer and multiple endocrine neoplasia type 2.

If you are considering GLP-1 therapy for weight management or diabetes and also smoke, a conversation with your provider about potential cessation benefits is warranted. However, smoking cessation should be a deliberate clinical decision made alongside evidence-based medications and behavioral support, not a secondary benefit assumed. Your provider should evaluate whether GLP-1 therapy aligns with your complete health picture and cessation goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context for how your individual reward-signaling pathways—reflected in GLP1R, GIPR, and FTO variants—respond to GLP-1 stimulation. These predispositions do not determine smoking addiction severity or cessation success, but they can support a more informed conversation with your provider about why certain appetite and reward-modulating treatments may work better for you.

The Precision Peptide Genetic Test reveals predispositions in four key peptide-pathway variants. In the context of smoking cessation, understanding your GLP1R and GIPR predispositions may help contextualize your overall dopamine and appetite sensitivity, which are neurobiologically linked to nicotine reward processing. However, genetic predisposition is not prediction—individual responses remain highly variable.

If you are exploring GLP-1 therapy alongside smoking cessation, your healthcare provider can use genetic insights alongside clinical assessment to design a personalized plan. PlexusDx compounded GLP-1 options (semaglutide, tirzepatide, and dual-compound GLP-Squared) are available through licensed 503A pharmacies, and your provider can discuss whether GLP-1 support fits into your broader cessation and metabolic health strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.